Biomarkers in active surveillance

The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging. In addition, monitoring protocols relying on serial biopsies is invasive and presents risks such as infection. For these reasons, there is substantial interest in identifying markers that can be used to improve AS selection and monitoring. In this article, we review the evidence on serum, urine and tissue markers in AS.

Translational andrology and urology. 2018 Feb [Epub]

Stacy Loeb, Jeffrey J Tosoian

Department of Urology, New York University, New York, NY, USA., The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.

email news signup